PHSE
Pharmhouse Corp
0.0127$
+32.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q1 21 | Q2 21 | Q3 21 | Q2 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.3% | 82.0% | 57.7% | 95.8% | 140.7% | 140.7% | 140.7% | 100.8% | 100.8% | 100.8% | 100.6% | 74.4% | 74.4% | – | – | – | – | – | – | 8,698.3% | -70.0% | 0.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | 21.2% | 22.9% | 23.8% | 24.7% | 23.4% | |
| 0.7% | 18.0% | 42.3% | 4.2% | -40.7% | -40.7% | -40.7% | -0.8% | -0.8% | -0.8% | -0.6% | 25.6% | 25.6% | – | – | – | – | – | – | -8,598.3% | 170.0% | 99.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | 78.8% | 77.1% | 76.2% | 75.3% | 76.6% | |
| 91.4% | 12.2% | 48.2% | 10.5% | 108.9% | 108.9% | 108.9% | 24.3% | 24.3% | 24.3% | 24.4% | 56.4% | 56.4% | – | – | – | – | – | – | 69,811.8% | 120.2% | 1,862.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | 124.8% | 486.3% | 204.5% | 148.4% | 261.4% | |
| -90.6% | 5.8% | -5.9% | -6.2% | -149.5% | -149.5% | -149.5% | -25.0% | -25.0% | -25.0% | -25.0% | -30.8% | -30.8% | – | – | – | – | – | – | -78,410.0% | 49.8% | -1,763.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | -46.0% | -409.2% | -128.3% | -73.2% | -184.8% | |
| 6.3% | 4.3% | 3.7% | 7.6% | 6.7% | 6.7% | 6.7% | 5.9% | 5.9% | 5.9% | 5.9% | 8.8% | 8.8% | – | – | – | – | – | – | – | 0.4% | 4.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | 4.3% | 0.8% | 0.1% | 8.5% | 3.1% | |
| -97.0% | 1.6% | -9.6% | -13.9% | -156.2% | -156.2% | -156.2% | -30.9% | -30.9% | -30.9% | -31.0% | -39.6% | -39.6% | – | – | – | – | – | – | -78,410.1% | 59.9% | -1,276.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -50.4% | -407.6% | -142.2% | -81.7% | -191.1% | |
| – | – | – | 4.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -97.0% | 1.6% | -9.6% | -18.8% | -156.2% | -156.2% | -156.2% | -30.9% | -30.9% | -30.9% | -31.0% | -39.6% | -39.6% | – | – | – | – | – | – | -78,410.1% | 59.9% | -1,276.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | -50.4% | -423.7% | -142.2% | -81.7% | -195.9% | |
| – | 5.8% | -5.9% | -6.2% | -149.6% | -149.6% | -149.6% | -10.0% | -10.0% | -10.0% | -10.1% | -15.7% | -15.7% | – | – | – | – | – | – | -69,711.8% | 60.3% | -1,271.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | -46.0% | -409.2% | -125.4% | -69.9% | -183.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.